Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
660 participants
OBSERVATIONAL
2016-12-31
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study expects to recruit 330 cases (malaria positive) and 330 control (negative cases) subject. One-to-one matching of cases (malaria positive) and controls (malaria negative) will be done at each study site.
CASE (Malaria positive) subject will go through the following;
1. Enrollment visit (Day 0)
1.1 Blood collection of three dried blood spots, and malaria slide. In district hospitals in individuals \>14 kg: additional 10ml venous blood will be collected.
1.2 A survey questionnaire which includes patient demographics, information on malaria treatment, bed net use and possible risk factors for acquiring malaria, as well as questions about their travel and usage of mobile phones will be administered.
2. Follow up visits (if fever plus Day 42 (+/-3))
2.1 Blood collection of three dried blood spots and malaria slide. In district hospitals: additional 0.5ml venous blood will be collected.
2.2 Short survey questionnaire including questions on symptoms, travel and possible risk behaviors since enrollment will be administered.
CONTROL (Malaria negative) subject will go through the following;
1. Enrollment visit (Day 0)
1.1 Blood collection to confirm negative malaria slide. In district hospitals: additional 0.5ml venous blood will be collected.
1.2 A survey questionnaire including patient demographics, information on any recent malaria treatment they may have taken, bed net use and possible risk factors for acquiring malaria, as well as questions about their travel and usage of mobile phones will be administered.
2. Follow up visit: No follow up visit
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day
NCT02020330
Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults
NCT02992119
Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic
NCT04416945
Malaria Genetic Surveillance in Cambodia
NCT03384472
Malaria Genetic Surveillance
NCT03384498
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients self-presenting to (1) health centres or(2) malaria posts or (3) district hospitals in Buntharik District and Nachalui District, Ubon Ratchathani Province, Thailand and requiring a diagnostic test for malaria as determined by the treating clinician will be recruited. Those who are malaria positive will be candidate cases and those who are malaria negative will be candidate controls.
One-to-one matching of cases and controls will be done at each study site. One control will be matched to each case. The matching criteria will be the next malaria negative patient to attend the study site of the same gender and age+/-5 years as an enrolled malaria positive case.
Study procedure:
CASE (Malaria patient defined by positive RDT or blood smear)
Upon enrollment, the below study procedures will be followed;
1. Blood samples consisting of:
* Three dried blood spots
* A microscopy slide
* In the district hospitals only, 10 ml of venous blood will be taken from the positive for malaria patient.
2. A survey include patient demographics, information on malaria treatment, bed net use and possible risk factors for acquiring malaria, as well as questions about their travel and usage of mobile phone will be administered to each patient.
CONTROL (Non-malaria patient defined by negative RDT or blood smear)
Upon enrollment, for those negative for malaria, the below study procedures will be follows;
1. Blood samples consisting of:
* Blood smear
* In the district hospitals only, 0.5 ml of venous blood will also be collected.
2. A survey include patient demographics, information on malaria treatment, bed net use and possible risk factors for acquiring malaria, as well as questions about their travel and usage of mobile phone swill be administered to each patient.
CASE: Follow-up
* If patients develop a fever after the end of antimalarial treatment and within 42 days after enrollment, they will be asked to return for follow-up as soon as possible on one occasion and then again at 42 (+/-3) days.
* If they do not develop fever within 42 days after enrollment, they will be asked to return for follow up at 42 (+/-3) days.
At the follow-up visit, blood will be taken to test for malaria by microscopy, three dried blood spots will be taken and a short survey administered including questions on symptoms, travel and possible risk behaviors since enrollment.
\*In the district hospitals only, 1.5ml of venous blood will be taken
CONTROL: No follow up
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Case
Malaria patient defined by positive RDT or blood smear
Interview
A survey will be included patient demographics, information on malaria treatment, bed net use and possible risk factors for acquiring malaria, as well as questions about their travel and usage of mobile phones
Blood collection (Dried Blood Spot)
Dried Blood Spot
Blood Collection (Venous Blood collection)
Venous Blood collection
Blood Smear
Slide blood smear
Control
Non-malaria patient defined by negative RDT or blood smear
Interview
A survey will be included patient demographics, information on malaria treatment, bed net use and possible risk factors for acquiring malaria, as well as questions about their travel and usage of mobile phones
Blood Collection (Venous Blood collection)
Venous Blood collection
Blood Smear
Slide blood smear
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Interview
A survey will be included patient demographics, information on malaria treatment, bed net use and possible risk factors for acquiring malaria, as well as questions about their travel and usage of mobile phones
Blood collection (Dried Blood Spot)
Dried Blood Spot
Blood Collection (Venous Blood collection)
Venous Blood collection
Blood Smear
Slide blood smear
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients of ≥ 6 months of age testing positive for malaria of any species as determined by a positive rapid diagnostic test (RDT) or asexual stage parasites on a smear of peripheral blood including individuals with more than one species of Plasmodium.
* Control (Non-malaria patient defined by negative RDT or blood smear):
* Patients \> 6 months of age requiring a diagnostic test for malaria but testing negative for malaria by rapid diagnostic test (RDT) or asexual stage parasites on a smear of peripheral blood. Controls will be age and gender matched to individual cases at each study site (details below).
Exclusion Criteria
6 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mahidol Oxford Tropical Medicine Research Unit
OTHER
University of Oxford
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Buntharik Hospital
Ubon Ratchathani, Ubon Rachatani, Thailand
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EPI1601
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.